What separates ChondroFiller from Arthrosamid

The question most patients arrive with is straightforward: which of these two injections is right for me? The answer requires a brief reframe — ChondroFiller and Arthrosamid are not alternatives competing for the same problem. They treat structurally different conditions in different parts of the same joint.

ChondroFiller is designed for a focal cartilage defect: a discrete area where the smooth articular surface covering the bone has worn away or been damaged. Arthrosamid is designed for diffuse knee osteoarthritis, where the joint's synovial lining — the tissue-lined capsule surrounding the cartilage — is chronically inflamed and mechanically overloaded. One addresses a localised failure of the cartilage layer itself; the other works within the synovial environment.

Choosing between them starts with an accurate diagnosis, not a preference. For patients presenting with both problems simultaneously — damaged cartilage and an inflamed synovial lining — the two injections can complement each other rather than compete. The sections below explain how each works, who it suits, and how a clinician determines which pathway, or combination, is appropriate.

How ChondroFiller works for focal cartilage defects

Think of articular cartilage as the smooth, load-bearing surface lining the ends of bones inside a joint — the layer that allows movement with minimal friction. A focal cartilage defect is a discrete breach in that surface: a defined area where the hyaline cartilage has been lost through injury, repetitive stress, or localised breakdown, leaving the underlying bone exposed. Unlike the diffuse thinning that characterises osteoarthritis across the whole joint, a focal defect is more like a pothole in a road surface — a bounded cavity in an otherwise intact structure, demanding a different kind of repair.

ChondroFiller® (manufactured by Meidrix Biomedicals GmbH, CE-marked as a Class III medical device) is an injectable collagen scaffold designed to fill that cavity and provide the body with a framework for repair. The product is an acellular Type I collagen solution — it contains no cells of its own. It is delivered as an ultrasound-guided outpatient injection from a ready-to-use two-chamber syringe, after which the collagen gels in place within approximately three to five minutes, forming a stable implant that conforms to the individual shape of the defect. No bone drilling, fibrin glue, or surgical incision is required.

Once positioned, the scaffold functions as a chemotactic matrix. Published data indicate that the patient's own repair cells migrate into the collagen structure and, over a period of several months, begin producing new hyaline-like cartilage tissue. Evidence suggests this process leads to measurable structural repair, though individual outcomes depend on defect size, location, and patient-specific factors. The approach is applicable across multiple joints — including the knee, hip, shoulder, and ankle — and can address defects up to 6 cm².

How Arthrosamid works for knee osteoarthritis

Knee osteoarthritis is not a single-point failure. It is a progressive, whole-joint condition in which cartilage gradually thins across broad areas of the joint surface, the synovial lining — the fibrous capsule enclosing the joint — becomes chronically inflamed, and biomechanical load through the knee shifts in ways that accelerate further damage. This diffuse, multi-tissue process is clinically quite different from the discrete cartilage breach described in the previous section, and it calls for a correspondingly different approach.

Arthrosamid® is a non-biodegradable injectable hydrogel developed by Contura International: 97.5% water and 2.5% cross-linked polyacrylamide, classified as a non-resorbable implant. Delivered as an ultrasound-guided intra-articular injection, it integrates into the synovial membrane rather than sitting on the cartilage surface itself. Once embedded, it acts as a permanent physical buffer within the joint environment — reducing friction, cushioning mechanical load, and providing a scaffold into which synovial lining cells can re-infiltrate over time (Henriksen et al., 2018; Tnibar et al., 2017).

Arthrosamid® does not regenerate cartilage. Its clinical benefit is biomechanical and symptomatic rather than structural repair of the articular surface. Published series suggest measurable pain reduction in the majority of suitable patients within the first year following a single injection. The treatment is indicated for mild-to-moderate knee osteoarthritis; it is not appropriate for severe bone-on-bone OA or inflammatory arthritides such as rheumatoid arthritis, where the underlying disease process requires a different management pathway entirely.

Matching the right injection to your diagnosis

The clinical picture matters as much as symptom severity. Two patients can report identical levels of knee pain — one with a discrete post-injury cartilage lesion, the other with diffuse osteoarthritic change — and the appropriate injection for each is entirely different.

Focal cartilage defects tend to present in younger or more active patients, or follow a specific injury or mechanical event. On MRI using a cartilage-sensitive sequence, they appear as a defined breach in the articular surface — a bounded area of damage with surrounding tissue that may be largely intact. The location, depth, and size of the lesion all shape what a suitable treatment looks like.

Osteoarthritis is diagnosed from a combination of clinical findings and imaging: joint space narrowing, subchondral bone changes, and diffuse cartilage thinning distributed across the joint surface on X-ray or MRI. Pain that worsens with prolonged activity, morning stiffness, and crepitus are characteristic features — but none of these alone reliably differentiates OA from a focal defect, which is why structural imaging is a necessary part of the assessment.

Some patients present with both pathologies simultaneously: a focal lesion sitting within a joint that also shows background osteoarthritic changes. In those cases, identifying which problem is dominant — and whether one or both injections might be relevant — depends on a careful clinical and imaging review rather than symptom history alone.

What the clinical evidence shows for each

Neither product has been assessed against the other in a head-to-head randomised trial — nor would such a trial be appropriate, given that they address different diagnoses in different anatomical compartments. Each evidence base needs to be read on its own terms.

ChondroFiller — published cohort data

The primary evidence comes from post-market clinical follow-up (PMCF) studies, most of which are manufacturer-sponsored — a limitation the data carry, and one worth weighing when interpreting effect sizes. Within that context, results across European cohorts are consistent. Published series report a mean improvement in IKDC (International Knee Documentation Committee) functional score of approximately 32 points at 12 months, sustained at three-year follow-up, with patients reaching a mean functional score of around 80. The established minimally clinically important difference for the IKDC is 16.7 points, placing these outcomes clearly above the threshold for clinical relevance. MRI assessments using the MOCART scoring system indicate greater than 80% defect filling and good integration of repair tissue with surrounding native cartilage by one year, progressing from a mean of around 65 at four weeks. Reoperation rates in published ChondroFiller series range from approximately 3–8%, comparing favourably with published figures for ACI/MACI (up to 37%) and microfracture (up to 41%), though no randomised head-to-head comparison exists in the literature.

Arthrosamid — registry cohort data

Arthrosamid® has a broader observational base in knee osteoarthritis. Published series and registry cohorts report meaningful pain relief in over 70% of suitable patients within the first year of a single injection, with effects extending across multi-year follow-up in several studies. A 2022 paper by Maulana, Cole, and Lee (Journal of Arthritis) identified a reduction in patellofemoral bone marrow lesions following a single iPAAG injection — a finding that, if replicated, would point to a structural benefit beyond symptom relief. However, this comes from a small, single study and requires independent confirmation. As with ChondroFiller, the observational design and degree of sponsor involvement in primary studies are limitations the data carry.

UK access

Neither ChondroFiller nor Arthrosamid has received NICE guidance or routine NHS commissioning. Both are currently available on a self-funded basis through specialist private practice, with suitability for either depending on careful clinical and imaging assessment of the underlying joint pathology.

When both injections can be used in the same session

For some patients, the question 'which injection is right for me?' has a more nuanced answer — because the underlying pathology is not one problem but two.

A focal cartilage defect and osteoarthritic synovial inflammation can coexist in the same joint. When structural assessment confirms both pathologies are clinically present and significant, there is a logical case for addressing each in the same outpatient appointment: one injection targeting the damaged cartilage surface, the other targeting the compromised synovial lining. The mechanisms do not overlap or interfere. ChondroFiller acts as a regenerative scaffold within the focal defect itself; Arthrosamid integrates into the synovial membrane as a mechanical cushion. Neither substitutes for the other's role.

Both are delivered as ultrasound-guided intra-articular injections, which makes same-session administration practically compatible. This is not, however, a default or routine combination. It is appropriate only when structural review confirms that both pathologies are present — not simply that a patient has knee pain and wants comprehensive treatment. No single injectable product can simultaneously restore a focal cartilage lesion and address diffuse synovial compromise; the case for combining lies precisely in the fact that each product does a categorically different job.

For patients who are unsure whether their symptoms reflect a focal lesion, background OA, or both, the most informative first step is a consultant assessment supported by cartilage-sensitive MRI — to establish which problems are actually present before any treatment pathway is considered.